DBV Technologies
France - ChâtillonBiotechnology
Focus: DBV Technologies is a France-based biotechnology company specializing in epicutaneous immunotherapy (EPIT) for allergic desensitization, representing a novel approach to allergy treatment through skin-patch delivery.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Open Jobs
0
About DBV Technologies
AI assessmentNot HiringNo open roles listed right now. Follow DBV Technologies to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
DBV712 250 mcg
Peanut AllergyClinical Trials (1)
NCT05424731Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
N/AHelp build intelligence for DBV Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.